Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Xiuping Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7460-1886; OpenAlex author ID A5101841412. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Metabolic syndrome worsens perioperative and oncological outcomes in patients with pancreatic ductal adenocarcinoma after R0 resection: A multicenter propensit… Co-author DOI 10.1016/j.hbpd.2026.06.001↗
  2. New-onset diabetes worsens prognosis of patients with pancreatic ductal adenocarcinoma after R0 resection: A multicenter study. Co-author DOI 10.1016/j.hbpd.2025.04.008↗
  3. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center. Co-author DOI 10.1016/j.hbpd.2022.09.006↗
  4. Derivation and validation of a preoperative prognostic model for resectable pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.hbpd.2022.09.009↗
  5. Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study. Co-author DOI 10.1097/js9.0000000000000296↗
  6. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02321-7↗
  7. A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduod… Co-author DOI 10.1016/j.ijsu.2022.106891↗
  8. Comment On "Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?" Co-author DOI 10.1097/sla.0000000000004410↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rong Liu · 8 shared papers, 2021–2026 · strength 1.58
  2. Zhiming Zhao · 7 shared papers, 2022–2026 · strength 1.36
  3. Minggen Hu · 4 shared papers, 2022–2023 · strength 0.74
  4. Shuai Xu · 3 shared papers, 2022–2025 · strength 0.56
  5. Shuai Xu · 3 shared papers, 2022–2023 · strength 0.55
  6. Qu Liu · 3 shared papers, 2022–2023 · strength 0.53
  7. Peizi Liu · 2 shared papers, 2025–2026 · strength 0.48
  8. Wan Yee Lau · 2 shared papers, 2022–2023 · strength 0.33
  9. Kai Liu · 1 shared paper, 2026 · strength 0.25
  10. Xiaodong Tan · 1 shared paper, 2025 · strength 0.23
  11. Wenbo Zou · 1 shared paper, 2023 · strength 0.19
  12. Nan Jiang · 1 shared paper, 2022 · strength 0.15
  13. Guanghai Dai · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.